- ISIN
- US44486Q1031
- CUSIP
- 44486Q103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 26, 2021
Highlights
- Market Cap
- $275.01M
- Enterprise Value
- $294.80M
- EPS (TTM)
- -$0.58
- Total Revenue (TTM)
- $2.02M
- Gross Profit (TTM)
- -$13.55M
- EBITDA (TTM)
- -$173.00M
- Year Range
- $0.55 - $2.93
- Target Price
- $3.00
- ROA (TTM)
- -88.27%
- ROE (TTM)
- -839.56%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HUMA Performance Chart
Humacyte, Inc. (HUMA) is up 44.7% since the beginning of the year. At $1 per share, HUMA is trading 52.6% below its 52-week high of $3.
Loading charts...
Returns By Period
Humacyte, Inc. (HUMA) has returned 44.72% so far this year and -46.95% over the past 12 months.
Humacyte, Inc.
- 1D
- -4.14%
- 1M
- 62.52%
- YTD
- 44.72%
- 6M
- 10.32%
- 1Y
- -46.95%
- 3Y*
- -26.84%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
HUMA Monthly Returns History
Based on dividend-adjusted daily data since Aug 26, 2021, HUMA's average daily return is +0.02%, while the average monthly return is +0.84%. At this rate, an investment would double in approximately 6.9 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jul 2024 with a return of +97.1%, while the worst month was Mar 2025 at -49.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, HUMA closed higher 45% of trading days. The best single day was Dec 20, 2024 with a return of +34.1%, while the worst single day was Oct 7, 2025 at -33.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.87% | 11.76% | -45.59% | 38.75% | 54.43% | 6.92% | 44.72% | ||||||
| 2025 | -9.31% | -25.76% | -49.85% | -14.96% | 84.14% | -21.72% | 14.83% | -35.42% | 12.26% | -4.02% | -19.16% | -28.85% | -80.98% |
| 2024 | 16.90% | 31.02% | -28.51% | 26.05% | 90.82% | -35.83% | 97.08% | -36.05% | -10.08% | -7.17% | -10.50% | 11.73% | 77.82% |
| 2023 | 24.64% | 16.35% | 0.98% | 4.85% | 5.86% | -16.62% | 14.69% | 16.77% | -23.50% | -27.65% | 25.00% | 7.17% | 34.60% |
| 2022 | -25.79% | 12.08% | 17.08% | 0.28% | -23.31% | -40.88% | 8.41% | 4.89% | -10.68% | 5.67% | -9.43% | -32.37% | -70.90% |
| 2021 | 33.39% | -20.59% | -21.62% | 19.01% | -33.06% | -33.85% |
Benchmark Metrics
Humacyte, Inc. has an annualized alpha of -16.78%, beta of 1.76, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since August 27, 2021.
- This stock participated in 220.69% of S&P 500 Index downside but only 79.91% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -16.78%
- Beta
- 1.76
- R²
- 0.10
- Upside Capture
- 79.91%
- Downside Capture
- 220.69%
Return for Risk
Risk / Return Rank
HUMA ranks 24 for risk / return — below 24% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Humacyte, Inc. (HUMA) and compare them to S&P 500 Index.
| HUMA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.42 | 2.39 | -2.81 |
Sortino ratioReturn per unit of downside risk | -0.01 | 3.25 | -3.27 |
Omega ratioGain probability vs. loss probability | 1.00 | 1.43 | -0.44 |
Calmar ratioReturn relative to maximum drawdown | -0.60 | 3.11 | -3.71 |
Martin ratioReturn relative to average drawdown | -0.92 | 14.38 | -15.30 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Humacyte, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Humacyte, Inc. was 96.62%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Humacyte, Inc. drawdown is 91.82%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -96.62%Mar 2026 | 4y 7mo | — | 4y 9moSep 2021 - now |
Drawdown Indicators
| HUMA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.62% | -56.78% | -39.84% |
Max Drawdown (1Y)Largest decline over 1 year | -78.96% | -9.10% | -69.86% |
Max Drawdown (3Y)Largest decline over 3 years | -93.93% | -18.90% | -75.03% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -91.82% | 0.00% | -91.82% |
Average DrawdownAverage peak-to-trough decline | -76.26% | -10.72% | -65.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 51.15% | 1.97% | +49.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Humacyte, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Humacyte, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HUMA relative to other companies in the Biotechnology industry. Currently, HUMA has a P/S ratio of 115.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HUMA in comparison with other companies in the Biotechnology industry. Currently, HUMA has a P/B value of 23.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with HUMA
Add Humacyte, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HUMA